Articles On Immutep (ASX:IMM)

Cancer immunotherapy developer Immutep Ltd [ASX:IMM] share price is trading neutral at time of writing, holding steady after flip-flopping between earlier gains and losses... The post Immutep Shares Hold Steady despite Operational Update (A...

The ASX 200 has rebounded from yesterday’s loss though the technology sector has weighed on the market for two consecutive weeks. The index closed 0.20 per cent higher, and is also up by 0.70 per cent for the week. IT slumped by another 2.5...

ShareCafeImmutep: A leader in a league alongside global Pharma giants Immutep (IMM.ASX) is one of the most promising drug developers listed on the ASX. The company’s lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), which is...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

The Immutep Ltd [ASX:IMM] share price is up 11.4% today after securing fast track designation from the US FDA for its eftilagimod alpha product. IMM shares were up as much as 17% in early trade... The post Immutep Share Price Soars on US F...

08 April 2021 - Biotechnology company Immutep (ASX:IMM) has received a fast-track approval from the United States Food and Drug Administration (FDA) for its lead product ‘efti’.

Immutep (ASX:IMM) shares have hit their highest level in early trade after the Sydney biotech company’s lead product candidate was green-lit for possible early regulatory approval in the United States. Immutep’s drug candidate eftilagimod a...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on form again and charging higher. At the time of writing, the benchmark index is up 1.1% to 7,006.3 points. Four ASX shares that are climbing more than most today are listed be...

Source:Khakimullin, Shutterstock Summary The ASX 200 on Thursday opened higher, up 13.70 points, or 0.20%, to 6,941.70, even as the US stock markets closed mixed overnight.   Metals & Mining and Resources were up by over 1%...

The Immutep Ltd (ASX: IMM) share price has been a strong performer again on Thursday. In morning trade, the biotechnology company’s shares are storming 10% higher to 48.5 cents. Why is the Immutep share price storming higher? Investors hav...

Immutep (ASX:IMM) has announced that the US FDA has granted fast-designation to its lead product candidate eftilagimod alpha.

S&P 500 at record high again, after release of Fed minutes S&P 500 has set a record high again, marking the 18th time it has done so this year. The index rose by 0.15%, after the Fed said it will continue ultra-low interest rates po...

Source:elwynn, Shutterstock Summary Nexion Group Ltd (ASX:NNG) on Thursday announced that it had completed agreement to acquire Blue Sky Telecom Pty Ltd as part of its growth strategy. The agreement to acquire 100 per cent of the issu...

Source:Khakimullin , Shutterstock Summary Immutep Ltd (ASX:IMM) announced that its lead product candidate eftilagimod alpha or efti had received fast track designation from the United States Food and Drug Administration (FDA). Efti ha...

Source: DG PhotoStock, Shutterstock Summary ASX-cannabis player Bod Australia has obtained a binding purchase order (PO) for CBD products in the US. Another cannabis player, MGC Pharmaceuticals, has completed the delivery of the first...

The Immutep Ltd (ASX: IMM) share price is climbing in late-morning trade after announcing a new European patent grant. At the time of writing, the biotechnology company’s shares are swapping hands for 44 cents, up 2.35%. What was announced...

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial. A cohort review committee has allowed the Phase 1 trial to move...

Wall Street slides, as IMF raises global growth forecast All major US indices slid on Tuesday, but stayed near record highs gained the previous day. Dow Jones closed 0.29% lower, S&P500 dropped 0.1%, while tech heavy NASDAQ slid 0.05%....

Australian company Immutep (ASX:IMM) says positive trial results from a new combination including Bristol Myers Squibb's PBS-listed OPDIVO (nivolumab) highlights the potential of its own lead candidate.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and is tumbling lower. At the time of writing, the benchmark index is down 0.2% to 6,812.2 points. Four ASX shares that are falling more than most to...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

Source:ShutterstockProfessional, Shutterstock Summary Lefroy Exploration has been making the headlines since the last month. The stock has shot up by over 63 per cent to A$1.125. Digital Wine Ventures has signed a memorandum of unders...

The best performer on the All Ordinaries index on Friday by some distance has been the Immutep Ltd (ASX: IMM) share price. In afternoon trade, the biotechnology company’s shares are up 29% to 44.5 cents. At one stage today, the Immutep sha...

Immutep (ASX:IMM) shares have spiked after Bristol Myers Squibb announced that a drug similar to Immutep’s lead candidate had succeeded in fighting cancer in a large study. Patients treated with Bristol Myer Squibb’s anti-LAG-3 monoclonal a...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Immutep (ASX:IMM) shares closed 10.5 per cent higher on Tuesday after the Sydney biotech announced it would collaborate with drug giant Merck & Co on another clinical trial. The two companies will hold a Phase IIb trial evaluating how t...

Source: CI Photos, Shutterstock Summary ASX-listed leading immunotherapy developer Immutep Limited entered into a second clinical trial collaboration with Merck & Co’s subsidiaries. Diagnostic company BARD1 Life Sciences revealed...

The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology...

Immutep (ASX:IMM), an Australian biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, has announced a second clinical trial collaboration and supply agreement with MS...

Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents. Immute...

The Immutep Ltd (ASX: IMM) share price is down 1.59% at the time of writing trading at 31 cents a share. This follows this morning’s announcement that Immutep is expanding Part B of its cancer treatment clinical trial. Let’s break down wha...

Summary Respiri Limited announced that Pharmacy Catalyst members to provide support to sales of wheezo with the in-pharmacy asthma management program. The Company would continue to introduce the program across several other members pha...

When it comes to biotech stocks, few are as ambitious as Immutep Ltd [ASX:IMM]. Because when they’re not battling to try and treat cancer, they’re busy trying to stave off COVID-19. Which is exactly what has sent the IMM share price climbin...

Immutep (ASX:IMM) shares are up nearly five per cent this morning after the Sydney biotech said a trial of its ... Read More The post Immutep Covid-19 trial moves forward in Czech Republic appeared first on Stockhead.

Summary Global biotech company Immutep announces the advancement in Phase 2 trial assessing eftilagimod alpha in COVID-19 patients. The Company said that positive recommendation from the DSMB builds on strong safety profile for eftilag...

A trial of biotechnology company Immutep's (ASX: IMM) experimental cancer drug on COVID-19 patients will go ahead, after a preliminary test found the immune boosting drug was safe for use. As a result Immutep will see the trial progress t...

Summary Active biotechnology player Immutep has completed enrolment and dosing for the last patient in the TACTI-002 trial. The Company expects further data from the study in the first half of 2021. Immutep has also commenced the enro...

The Immutep Ltd (ASX: IMM) share price has failed to rally this morning after the company released an update on its cancer trial. The Sydney based biotechnology company’s share price lifted 1.23% to 41 cents in early morning trade, but has...

It has been a disappointing day for the S&P/ASX 200 Index (ASX: XJO) on Wednesday. In afternoon trade, the benchmark index is down 0.8% to 6,648.5 points. Four shares that have not let that hold them back today are listed below. Here’s...

In morning trade the Immutep Ltd (ASX: IMM) share price is storming higher following the release of an announcement. At the time of writing, the biotechnology company’s shares are up 9% to 42.5 cents. What did Immutep announce? This mornin...

Summary Immutep Ltd (ASX:IMM) received a US patent for its lead active immunotherapy candidate eftilagimod alpha along with a PD-1 pathway inhibitor. The United States Patent & Trade Mark Office has granted the patent number 10,874...

ShareCafeImmutep: fighting the good fight Immutep (ASX: IMM) are global leaders in the understanding and development of immunotherapy drugs for cancer and autoimmune diseases. IMM’s objective is to harness and strengthen the power of the bo...

The Immutep Ltd (ASX: IMM) share price is on watch this morning on news the company will significantly upscale its manufacturing capacity. The Immutep share price finished Wednesday’s trading session at 43 cents, up 6.1%. Immutep is a biot...

The Immutep Ltd (ASX: IMM) share price is on fire today, rising close to 60%. Immutep shares closed at 28 cents a share yesterday afternoon but opened at 45 cents this morning before rising to a high of 54 cents. The Immutep share price ha...

Immutep Limited (ASX: IMM) announced that its Chinese partner, EOC Pharma, will begin a new Phase II clinical trial on up to 152 metastatic breast cancer patients in China. Immutep Limited is a biotechnology company, which develops novel i...

Small-cap immunotherapy company Immutep Ltd [ASX:IMM] is absolutely flying today. The IMM share price is up 57.14% at time of writing. Spiking on some fantastic news the company had to share this morning.... The post Immutep Shares Soar 57%...

ShareCafeAustralia…One Hour In…ASX down 30 points ASX200 down 30 points (0.5%) to 6693.   UK PM Boris Johnson has been in Brussels trying to sort out Brexit and the news services are saying that “UK PM’s dinner with EU chief ends “with very...

Immunotherapy company Immutep (ASX:IMM) has announced what it describes as promising overall survival data from a breast cancer trial of its eftilagimod alpha and that its Chinese partner, EOC Pharma, will commence a new phase two c...